Briacell Therapeutics CORP. 8-K Filing
Ticker: BCTXZ · Form: 8-K · Filed: Dec 1, 2025 · CIK: 1610820
Sentiment: neutral
Filing Stats: 598 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-11-28 20:15:51
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex99-1.htm (EX-99.1) — 298KB
- ex99-2.htm (EX-99.2) — 315KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- ex99-1_002.jpg (GRAPHIC) — 22KB
- ex99-1_003.jpg (GRAPHIC) — 3KB
- ex99-1_004.jpg (GRAPHIC) — 5KB
- ex99-2_001.jpg (GRAPHIC) — 14KB
- ex99-2_001a.jpg (GRAPHIC) — 77KB
- ex99-2_004.jpg (GRAPHIC) — 58KB
- ex99-2_005.jpg (GRAPHIC) — 67KB
- ex99-2_006.jpg (GRAPHIC) — 40KB
- ex99-2_007.jpg (GRAPHIC) — 17KB
- ex99-2_008.jpg (GRAPHIC) — 55KB
- 0001493152-25-025469.txt ( ) — 1471KB
- bctx-20251128.xsd (EX-101.SCH) — 4KB
- bctx-20251128_def.xml (EX-101.DEF) — 26KB
- bctx-20251128_lab.xml (EX-101.LAB) — 36KB
- bctx-20251128_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 7KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams November 28, 2025 William V. Williams President and Chief Executive Officer